[Rockville, Maryland, October 3, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company participated in the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and...

HighTide Therapeutics Inc., a globally focused clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholang

Dr. Liping Liu, Founder & CEO of HighTide will present at the 25th Annual Future Leaders In The Biotech Industry on 23rd March 2018 in New York City. Dr. Liu will highlight HighTide’s product pipeline and development strategy. The...